Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration^*

References

• Collins AJ, Li S, Gilbertson DT, Liu J, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 2003;64(Suppl):S24–S31
   Google Scholar
• Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418–23
   PubMed Web of Science ®Google Scholar
• US Renal Data System, USRDS 2005 Annual data report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005
   Google Scholar
• Thorp ML, Eastman L, Smith DH, Johnson ES. Managing the burden of chronic kidney disease. Dis Manag 2006;9:115–21
   PubMedGoogle Scholar
• Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the renal research institute-CKD study. Am J Kidney Dis 2005;45:658–66
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Kent GM, et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000;11:912–6
   PubMed Web of Science ®Google Scholar
• Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003;18\(Suppl 2):ii7–ii12
   Google Scholar
• Macdougall IC. Present and future strategies in the treatment of renal anaemia. Nephrol Dial Transplant 2001;16(Suppl 5):50–5
   PubMedGoogle Scholar
• Collins AJ. Anaemia management prior to dialysis: cardiovascular and benefit observations. Nephrol Dial Transplant 2003;18 (Suppl 2):ii2–ii6
   Google Scholar
• Ross SD, Fahrbach K, Frame D, et al. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003;25:1786–805
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004:19:121–32
   PubMed Web of Science ®Google Scholar
• Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181–91
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Bárány P, et al.; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 (Suppl 2):ii1–ii47
   Google Scholar
• Anon. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S11–S145
   PubMedGoogle Scholar
• Valderrábano F, Hörl WH, Macdougall IC, et al. PRE-dialysis survey on anemia management. Nephrol Dial Transplant 2003;18:89–100
   PubMed Web of Science ®Google Scholar
• Jadoul M, Vanrenterghem Y, Foret M, et al.; on behalf of the Darbepoetin Alfa 20000144 Study Group. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004;19: 898–903
   Google Scholar
• Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436–40
   PubMedGoogle Scholar
• Brandt M, Lanzendörfer M, Frische J, et al. Different receptor binding activity of C.E.R.A. (Continuous Erythropoietin Receptor Activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transplant 2006;21\(Suppl 4):iv9 [abstract SO018]
   Google Scholar
• Dougherty FC, Reigner B, Jordan P, Pannier A. Continuous Erythropoiesis Receptor Activator (CERA) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol 2004;15\(Suppl 3):iii157 [abstract 592P]
   Google Scholar
• Macdougall IC, Reigner B, Dougherty FC. Consistent pharmaco-kinetic properties of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in healthy volunteers and in patients with CKD. Am J Kidney Dis 2006;47:A41 [abstract 89]
   Google Scholar
• Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211–5
   PubMed Web of Science ®Google Scholar
• de Francisco ALM, Sulowicz W, Klinger M, et al.; on behalf of the BA16260 Study Investigators. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006;60: 1687–96
   Google Scholar
• Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392–5
   PubMed Web of Science ®Google Scholar
• Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa. Results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006;45:503–10
   Google Scholar
• Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337–43
   PubMed Web of Science ®Google Scholar
• Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial 2006;19:1–4
   PubMed Web of Science ®Google Scholar
• Strippoli GFM, Tognoni G, Navaneethan SD, et al. Haemoglobin targets: we were wrong, time to move on. Lancet 2007;369:346–50
   PubMed Web of Science ®Google Scholar
• Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111–24
   Google Scholar
• Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481–8
   PubMed Web of Science ®Google Scholar